Get started
Author

Jitendra G. Gandhi

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial
2022 · Nicholas J. Vogelzang, Tomasz M. Beer, et al. · JAMA Oncology · 105
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: A randomized phase 3 trial of the Minnie Pearl Cancer Research Network
2007 · John D. Hainsworth, David R. Spigel, et al. · Cancer · 72
Paclitaxel/Carboplatin/Gemcitabine Versus Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network
2007 · F. Anthony Greco, David R. Spigel, et al. · Clinical Lung Cancer · 21
Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
2011 · Ramaswamy Govindan, Daniel Morgensztern, et al. · Journal of Thoracic Oncology · 19
PDF
Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
2017 · Richard Kim, E Gabriela Chiorean, et al. · British Journal of Cancer · 17
PDF
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer
2015 · Daniel P. Petrylak, Jitendra G. Gandhi, et al. · Investigational New Drugs · 15
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.
2013 · Daniel Petrylak, Jitendra G. Gandhi, et al. · Journal of Clinical Oncology · 13
Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC).
2012 · Daniel Peter Petrylak, Jitendra G. Gandhi, et al. · Journal of Clinical Oncology · 7
A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer
2010 · David R. Spigel, John D. Hainsworth, et al. · Journal of Thoracic Oncology · 6
Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium
2009 · John D. Hainsworth, Anthony A. Meluch, et al. · Cancer Investigation · 6
Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).
2013 · Lauren Byers, Leora Horn, et al. · Cancer Research · 5
A New Low Ionic Strength Test for Assessment of Pretransfusion Compatibility. Studies In Vitro and In Vivo
1983 · Irma O. Szymanski, Jitendra G. Gandhi · American Journal of Clinical Pathology · 3
Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor, in combination with gemcitabine in patients with advanced pancreatic cancer.
2013 · Sameer A. Mahesh, Nashat Y. Gabrail, et al. · Journal of Clinical Oncology · 2
Studies on Low-Dose Hydroxyethyl Starch Leukapheresis
1984 · Irma O. Szymanski, Richard A. Teno, et al. · Vox Sanguinis · 1
Works count: 14
Citation count: 292
H-index: 7
I10-index: 7
Year
Topic
Type